01.09.17
CSSi LifeSciences has entered a strategic partnership with Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC), a nonprofit Contract Manufacturing Service Unit operated by Colorado State University. CSSi LifeSciences has preclinical, regulatory and clinical expertise, while BioMARC produces biopharma products for non-clinical, clinical, and commercial use.
BioMARC and CSSi LifeSciences will work together to create an accelerated, cost-effective GMP and clinical development solution to reduce complexity, expense and time developing a new biologic or vaccine. The two companies offer experience in process development and cGMP manufacturing using validated processes, as well as preclinical, CMC and global regulatory development and clinical operations.
"We are very pleased to establish this collaborative partnership with BioMARC," said Jim Sergi, president, CSSi LifeSciences. "We recognize the size and complexity of advanced development solutions for the manufacture and regulated release of viral vaccines and biologics, and are excited to provide a single-source solution to complement BioMARC's internal resources. CSSi LifeSciences™ is committed to providing BioMARC with the integrated services and resources needed to grow its business and expand its offerings further into the market."
Dennis Pierro, Ph.D., director of BioMARC, said, "The partnership with CSSi LifeSciences significantly strengthens our core capabilities and service offerings in the area of product lifecycle management," he said. "CSSi LifeSciences' broad experience and expertise in regulated products means that we can now better help vaccine and biologic developers efficiently move products into the marketplace to the benefit of patients."
BioMARC and CSSi LifeSciences will work together to create an accelerated, cost-effective GMP and clinical development solution to reduce complexity, expense and time developing a new biologic or vaccine. The two companies offer experience in process development and cGMP manufacturing using validated processes, as well as preclinical, CMC and global regulatory development and clinical operations.
"We are very pleased to establish this collaborative partnership with BioMARC," said Jim Sergi, president, CSSi LifeSciences. "We recognize the size and complexity of advanced development solutions for the manufacture and regulated release of viral vaccines and biologics, and are excited to provide a single-source solution to complement BioMARC's internal resources. CSSi LifeSciences™ is committed to providing BioMARC with the integrated services and resources needed to grow its business and expand its offerings further into the market."
Dennis Pierro, Ph.D., director of BioMARC, said, "The partnership with CSSi LifeSciences significantly strengthens our core capabilities and service offerings in the area of product lifecycle management," he said. "CSSi LifeSciences' broad experience and expertise in regulated products means that we can now better help vaccine and biologic developers efficiently move products into the marketplace to the benefit of patients."
